Cedilla

Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology

Retrieved on: 
Thursday, June 1, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Cyclin E, CDK2, Third Rock Ventures, Standard of care, Cedilla, Cancer, Therapy, Safety, Pharmaceutical industry, Bayer

Bayer and Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced an exclusive license agreement to develop and commercialize Cedilla Therapeutics’ CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers.

Key Points: 
  • Bayer and Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced an exclusive license agreement to develop and commercialize Cedilla Therapeutics’ CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers.
  • Overexpression or genetic activation of Cyclin Dependent Kinase 2 (CDK2) binding partner cyclin E is a key oncogenic process in several cancers.
  • Cedilla’s small molecules conditionally modulate the protein complex in its functional state resulting in highly selective inhibition.
  • Cedilla will also be eligible to receive royalties on medicines based on their technology commercialized by Bayer.

Cedilla Therapeutics Announces Appointment of Véronique Riethuisen as Chief Business Officer and Head of Finance

Retrieved on: 
Monday, April 5, 2021
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Cedilla, Turkish language

Cedilla Therapeutics, a venture-backed preclinical biotechnology company developing novel small molecules for cancer and other diseases, today announced the appointment of Vronique Riethuisen as Chief Business Officer and Head of Finance.

Key Points: 
  • Cedilla Therapeutics, a venture-backed preclinical biotechnology company developing novel small molecules for cancer and other diseases, today announced the appointment of Vronique Riethuisen as Chief Business Officer and Head of Finance.
  • She has an impressive track record shaping and building early and late-stage portfolios for leading biopharmaceutical companies, said Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics.
  • Vroniques substantial leadership experience, coupled with her background in corporate and business development, will be instrumental in growing Cedilla.
  • Ms. Riethuisen brings over 25 years of experience in global business development, M&A and alliance management leadership to Cedilla.

Cedilla Therapeutics Appoints Justin Birtz as Vice President, People and Culture

Retrieved on: 
Wednesday, October 23, 2019
Biotechnology, Pharmaceutical, Health, Oncology, Cedilla, Turkish language

Cedilla Therapeutics , a preclinical biotech company harnessing protein stability to create the next generation of targeted cancer therapies, today announced the appointment of Justin Birtz as vice president, people and culture.

Key Points: 
  • Cedilla Therapeutics , a preclinical biotech company harnessing protein stability to create the next generation of targeted cancer therapies, today announced the appointment of Justin Birtz as vice president, people and culture.
  • Mr. Birtz joins Cedilla from BitSight, where he was director, people operations.
  • In his role at Cedilla, Mr. Birtz will align Cedillas mission, values and talent strategy to connect, engage and develop remarkable professionals who share a passion for improving the lives of patients.
  • While adding to industry knowledge of protein degradation, Cedilla is building a powerful, industry-leading platform and broad pipeline of therapeutics.

Cedilla Therapeutics Appoints Delphine Collin, Ph.D., as Vice President, Biomolecular Sciences

Retrieved on: 
Tuesday, May 14, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Cedilla, Turkish language, Small molecule

Cedilla Therapeutics today announced the appointment of Delphine Collin, Ph.D., as vice president, biomolecular sciences.

Key Points: 
  • Cedilla Therapeutics today announced the appointment of Delphine Collin, Ph.D., as vice president, biomolecular sciences.
  • Delphine is an accomplished leader with a proven track record of developing successful discovery strategies and advancing preclinical projects, said Brian Jones, Ph.D., Cedillas chief scientific officer.
  • Were committed to broadening the reach of small molecule therapeutics to address cancer and other diseases caused by protein dysregulation.
  • Cedilla is focused on destabilizing oncoprotein targets using a product engine that is also applicable to targets outside of oncology.

Cedilla Therapeutics Expands Leadership Team with Appointment of Chief Human Resources Officer

Retrieved on: 
Monday, February 4, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Cedilla, Turkish language

Cedilla Therapeutics , a biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into protein stability, today announced the appointment of a veteran biopharma executive, Andrew Dawson, as chief human resources officer.

Key Points: 
  • Cedilla Therapeutics , a biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into protein stability, today announced the appointment of a veteran biopharma executive, Andrew Dawson, as chief human resources officer.
  • Were delighted to welcome Andrew to Cedilla as we continue to build out our team and expand our capabilities in drug discovery and development, said Alexandra Glucksmann, Cedillas president and chief executive officer.
  • Dawson brings more than 20 years of global experience in human resources across the biotech and pharmaceutical industries.
  • Most recently, he was a senior vice president and head of human resources at Enzyvant, leading the worldwide human resources function and serving as a member of the executive leadership team.